Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India
· Delayed Price · Currency is INR 210.97
-1.29 (-0.61%)
May 20, 2025, 3:30 PM IST
Jagsonpal Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 2,687 | 2,087 | 2,367 | 2,176 | 1,879 | Upgrade
|
| Revenue | 2,687 | 2,087 | 2,367 | 2,176 | 1,879 | Upgrade
|
| Revenue Growth (YoY) | 28.76% | -11.83% | 8.79% | 15.77% | 18.53% | Upgrade
|
| Cost of Revenue | 964.38 | 805.48 | 926.98 | 896.91 | 812.37 | Upgrade
|
| Gross Profit | 1,723 | 1,282 | 1,440 | 1,279 | 1,067 | Upgrade
|
| Selling, General & Admin | 641.29 | 632.64 | 729.76 | 703.71 | 658.72 | Upgrade
|
| Other Operating Expenses | 502.74 | 274.83 | 269.53 | 319.67 | 209.64 | Upgrade
|
| Operating Expenses | 1,293 | 1,065 | 1,101 | 1,039 | 879.22 | Upgrade
|
| Operating Income | 429.4 | 216.67 | 338.85 | 239.87 | 187.86 | Upgrade
|
| Interest Expense | -9.58 | -7.77 | -2.78 | -2.61 | -4.28 | Upgrade
|
| Interest & Investment Income | - | 85.92 | 34.28 | 15.46 | 29.92 | Upgrade
|
| Other Non Operating Income (Expenses) | 81.9 | 3.87 | 3.11 | 1.5 | 5.21 | Upgrade
|
| EBT Excluding Unusual Items | 501.72 | 298.69 | 373.46 | 254.22 | 218.72 | Upgrade
|
| Impairment of Goodwill | - | - | -0.3 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 5.92 | 11.35 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 3.59 | 0.85 | - | Upgrade
|
| Asset Writedown | - | - | -27.79 | - | - | Upgrade
|
| Other Unusual Items | 196.87 | - | -6.8 | - | - | Upgrade
|
| Pretax Income | 698.59 | 298.69 | 348.08 | 266.42 | 218.72 | Upgrade
|
| Income Tax Expense | 144.98 | 74.06 | 80.87 | 77.87 | 48.14 | Upgrade
|
| Net Income | 553.61 | 224.63 | 267.21 | 188.55 | 170.58 | Upgrade
|
| Net Income to Common | 553.61 | 224.63 | 267.21 | 188.55 | 170.58 | Upgrade
|
| Net Income Growth | 146.45% | -15.93% | 41.72% | 10.53% | 116.73% | Upgrade
|
| Shares Outstanding (Basic) | 67 | 66 | 65 | 65 | 65 | Upgrade
|
| Shares Outstanding (Diluted) | 67 | 66 | 65 | 65 | 65 | Upgrade
|
| Shares Change (YoY) | 1.46% | 1.35% | - | - | - | Upgrade
|
| EPS (Basic) | 8.26 | 3.40 | 4.08 | 2.88 | 2.60 | Upgrade
|
| EPS (Diluted) | 8.22 | 3.38 | 4.08 | 2.88 | 2.60 | Upgrade
|
| EPS Growth | 142.91% | -17.06% | 41.72% | 10.55% | 117.00% | Upgrade
|
| Free Cash Flow | 549.52 | 349.18 | 463.37 | 58.65 | 277.53 | Upgrade
|
| Free Cash Flow Per Share | 8.16 | 5.26 | 7.08 | 0.90 | 4.24 | Upgrade
|
| Dividend Per Share | 2.500 | 2.000 | 2.000 | 1.600 | 0.400 | Upgrade
|
| Dividend Growth | 25.00% | - | 25.00% | 300.00% | 100.00% | Upgrade
|
| Gross Margin | 64.11% | 61.41% | 60.84% | 58.78% | 56.78% | Upgrade
|
| Operating Margin | 15.98% | 10.38% | 14.31% | 11.02% | 10.00% | Upgrade
|
| Profit Margin | 20.60% | 10.76% | 11.29% | 8.67% | 9.08% | Upgrade
|
| Free Cash Flow Margin | 20.45% | 16.73% | 19.57% | 2.70% | 14.77% | Upgrade
|
| EBITDA | 510.71 | 221.73 | 347.11 | 255.13 | 198.72 | Upgrade
|
| EBITDA Margin | 19.01% | 10.62% | 14.66% | 11.73% | 10.57% | Upgrade
|
| D&A For EBITDA | 81.31 | 5.06 | 8.26 | 15.26 | 10.86 | Upgrade
|
| EBIT | 429.4 | 216.67 | 338.85 | 239.87 | 187.86 | Upgrade
|
| EBIT Margin | 15.98% | 10.38% | 14.31% | 11.02% | 10.00% | Upgrade
|
| Effective Tax Rate | 20.75% | 24.80% | 23.23% | 29.23% | 22.01% | Upgrade
|
| Revenue as Reported | 2,769 | 2,180 | 2,424 | 2,210 | 1,923 | Upgrade
|
| Advertising Expenses | - | 138.58 | 147.3 | 102.19 | 96.22 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.